TABLE 2.
Interpretation of the ACCORD-Lipid trial within news articles and biomedical journal articles published in the 15 months after trial publication, stratified by description of fenofibrate effectiveness in the trial.
| NEWS | ||||
|---|---|---|---|---|
| Description of fenofibrate effectiveness in ACCORD-Lipid trial | Recommendation for fibrate use made within article, No. (%) | Recommendation for fibrate use in light of discussing ACCORD-Lipid trial, No. (%)* | ||
| Supportive | Neutral | Unsupportive | ||
| Total (N = 67) | 23 (34.3%) | 12 (52.2%) | 5 (21.7%) | 6 (26.1%) |
| Effective (N = 11) | 9 (81.8%) | 7 (77.8%) | 1 (11.1%) | 1 (11.1%) |
| Mixed (N = 36) | 11 (30.6%) | 5 (45.5%) | 4 (11.1%) | 2 (5.6%) |
| Ineffective (N = 20) | 3 (15.0%) | 0 (0.0%) | 0 (0.0%) | 3 (100.0%) |
| BIOMEDICAL LITERATURE | ||||
|---|---|---|---|---|
| Description of fenofibrate effectiveness in ACCORD-Lipid trial | Recommendation for fibrate use made within article, No. (%) | Recommendation for fibrate use in light of discussing ACCORD-Lipid trial, No. (%)* | ||
| Supportive | Neutral | Unsupportive | ||
| Total (N = 141) | 77 (54.6%) | 52 (67.5%) | 13 (16.9%) | 12 (15.6%) |
| Effective (N = 28) | 21 (75.0%) | 19 (90.5%) | 2 (9.5%) | 0 (0.0%) |
| Mixed (N = 71) | 47 (66.2%) | 33 (70.2%) | 8 (17.0%) | 6 (12.8%) |
| Ineffective (N = 42) | 9 (21.4%) | 0 (0.0%) | 3 (33.3%) | 6 (66.7%) |
*
Proportion calculated only among those articles that made a recommendation about fibrate use.